- Heteroaromatic acetamide derivative, preparation and applications thereof
-
The present invention provides a heteroaromatic acetamide derivative, a preparation and applications thereof, wherein the derivative comprises a pharmaceutically acceptable salt and/or a solvate thereof. According to the present invention, the experiment results prove that the heteroaromatic acetamide derivative can specifically bind to transient receptor potential ankyrin 1 (TRPA1) and inhibit orreduce the activity of TRPA1, and can be used for treating diseases mediated by TRPA1; and the inhibitor of the present invention further comprises a pharmaceutical composition of the compound, and amethods for preparing the compounds. The derivative has a general formula defined in the specification.
- -
-
Paragraph 0030; 0032; 0034-0035
(2019/11/04)
-
- SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
-
Provided herein are novel heteroaryl compounds, pharmaceutically acceptable salts and pharmaceutical formulations thereof for selectively inhibiting serotonin reuptake and/or acting as 5-HT1A receptor agonists. Also provided herein are pharmaceutical compositions comprising the heteroaryl compounds and methods of using the pharmaceutical compositions in treating central nervous system (CNS) dysfunction in a mammal, especially a human being.
- -
-
Paragraph 00189; 00246
(2015/02/25)
-
- 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
-
The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
- -
-
Page/Page column 37
(2008/06/13)
-
- PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS
-
The invention provides a compound of formula (I) where R1, R2, R3, A, n, and p are disclosed herein) or a pharmaceutically acceptable salt thereof (a "2-Pyrimidinylpiperazine Compound"); pharmaceutical compositions compris
- -
-
Page 241-242
(2008/06/13)
-